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The incidence of squamous cell carcinoma
of the head and neck (HNSCC) reaches
as high as 16.5 cases per 100,000 indi-
viduals in the United States (1). Early-
stage lesions have a favorable prognosis
when treated surgically, but approximately
two-thirds of HNSCC are diagnosed at an
advanced locoregional stage (2). Chemora-
diation is the backbone of treatment for
the majority of advanced tumors, and is
associated with up to 80% long-term sur-
vival for patients with positive prognostic
features (3). Notably, the success of geno-
toxic therapy for advanced HNSCC far
exceeds non-surgical control rates for the
majority of epithelial tumors. Moreover,
the primary benefit from chemotherapy
for HNSCC is conferred not through a
decrease in distant metastases but through
enhanced local control (4, 5). As such, sig-
nificant efforts have been dedicated to elu-
cidating the molecular drivers of HNSCC
genesis and identifying the pathways that
sensitize these malignancies to the effects
of chemoradiation.
Infection with high-risk human papil-
loma virus (HPV) subtypes has emerged
as an important risk factor for HNSCC.
Unlike lesions associated with excessive
tobacco and alcohol use, TP53 mutations
are rarely found in HPV-positive HNSCC,
which is generally associated with a favor-
able clinical course (6). Despite this associ-
ation, no targeted therapies against HPV
oncogenes are available for the treat-
ment of patients with HNSCC. Similarly,
genetic and epigenetic aberrations of the
H-RAS, NOTCH, PI3K/Akt, BRCA1, and
TGF-β pathways have also been associ-
ated with HNSCC, but targeted agents
remain in preclinical stages for HNSCC
(2). In contrast, epidermal growth fac-
tor receptor (EGFR) inhibition combined
with radiotherapy is an effective strat-
egy for HNSCC (7). EGFR is upregulated
in approximately 90% of HNSCCs, and
expression level is an independent determi-
nant for decreased survival and impaired
locoregional control (8, 9). However, EGFR
inhibitors as monotherapy have produced
only modest clinical outcomes, and sur-
vival from HNSCC has not improved in
recent decades. Consequently, enhanced
understanding of the molecular carcino-
genesis of HNSCC is required to facilitate
development of new treatments.
Using an in vivo RNA interference
(RNAi) strategy to screen for driver muta-
tions involved in tumorigenesis, Schramek
and colleagues recently reported a novel
link between cutaneous squamous-cell car-
cinoma (CSCC), HNSCC, and impaired
DNA damage response (DDR) signaling
(10). To do so, a lentivirus-mediated RNAi
library was selectively delivered to the
surface ectoderm in utero under ultra-
sound guidance in a TGF-β-receptor-II
conditional knockout murine model of
CSSC and HNSCC. Selection of mul-
tiple independent small hairpin RNAs
(shRNAs) in three or more tumors yielded
eight potential tumor suppressors. Among
these lesions, 40% were enriched with
shRNAs againstMyh9, which encodes non-
muscle myosin IIa heavy chain. When
conditionally suppressed in mice with
endogenous TGF-β signaling, loss of
myosin IIa was sufficient for development
of CSCC, albeit with a significantly longer
latency. By activating the DDR pathway,
Schramek et al. further demonstrate that
both myosin IIa suppression and small
molecule inhibition delay and reduce p53
activation in response to double strand
breaks. Consistently, loss of myosin IIa
reduces the expression of p53-responsive
genes, including p21, Fas, Bax, Mdm2, and
14-3-3σ. Finally, biochemical assays and
microscopy both indicate that p53 fails to
accumulate and/or remain in the nucleus
in the absence of endogenous myosin IIa
activity.
These findings suggest a new role for
myosin IIa as a tumor suppressor that facil-
itates the DDR through stabilization of
p53 in the nucleus. Although the present
data pertain to CSSC and HNSCC, it
is intriguing to consider a broader role
for myosin IIa in oncogenesis and the
DDR. Also notable from this work is the
non-invasive, ultrasound-guided method
of selective shRNA delivery in utero. This
novel technique circumvents the immuno-
logical and physiological confounders of
orthotopic transplantation, and stands to
have broad applications for future genet-
ics screens. However, hairpin efficiency is a
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central component of RNAi and may bias
data away from biological reality. Consis-
tent with this limitation, TP53, which is
frequently mutated in HNSCC, was not
identified as a carcinogenic driver in the
present study, presumably secondary to
hairpin inefficiency.
Despite the abundance of murine data
presented by Schramek et al., the patho-
physiological relevance of Myh9 loss for
human malignancy remains uncertain. In
this regard, approximately 80% of myosin
IIa null HNSCCs in humans show con-
comitant loss of the TGF-β pathway, sug-
gesting that myosin IIa loss may not be
a direct oncogenic driver (10). Further-
more, a mere 30–40% of mice with intact
TGF-β signaling develop tumors follow-
ing Myh9 suppression and only do so
after a mean latency of 1 year. Indeed,
less than one-quarter of human SCCs and
fewer than one-third of human HNSCCs
show weak or absent immunolabeling for
myosin IIa. Therefore, rather than func-
tioning as a primary oncogenic driver in
human malignancy, Myh9 mutation may
play an accessory role in the genesis or
progression of certain HNSCC subsets. In
sum, it is likely that inactivating mutations
of myosin IIa have a low penetrance in
human HNSCC, as was suggested by the
initial sequencing effort that identified a
link betweenMyh9 and HNSCC (11). Nev-
ertheless, these results provide compelling
evidence that aberrant activity of the DDR
is associated with HNSCC and further sup-
port the hypothesis that these tumors are
both biologically and genetically diverse.
Further studies are necessary to establish
whether Myh9 mutation is of robust prog-
nostic significance and if DDR pathways
can be manipulated to enhance the efficacy
of treatment for HNSCC.
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